| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 0 | 9.279 | 11.105 | 9.259 | 11.789 |
| Total Income - EUR | - | - | - | - | - | 0 | 9.329 | 11.108 | 9.259 | 11.789 |
| Total Expenses - EUR | - | - | - | - | - | 17.782 | 14.335 | 12.713 | 13.103 | 19.884 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -17.782 | -5.006 | -1.605 | -3.844 | -8.095 |
| Net Profit/Loss - EUR | - | - | - | - | - | -17.782 | -5.006 | -1.703 | -3.937 | -8.449 |
| Employees | - | - | - | - | - | 1 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Mirumarc Therapy S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 2.820 | 2.116 | 1.421 | 730 | 29.816 |
| Current Assets | - | - | - | - | - | 3.481 | 4.442 | 3.754 | 4.097 | 3.477 |
| Inventories | - | - | - | - | - | 3.065 | 2.710 | 2.840 | 2.831 | 0 |
| Receivables | - | - | - | - | - | 0 | 408 | 651 | 528 | 1.259 |
| Cash | - | - | - | - | - | 416 | 1.324 | 263 | 739 | 2.219 |
| Shareholders Funds | - | - | - | - | - | -17.740 | -22.353 | -24.125 | -27.988 | -36.281 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 57.214 | 61.450 | 61.940 | 65.357 | 69.575 |
| Income in Advance | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8699 - 8699" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - Mirumarc Therapy S.r.l.